- Home
- SKHY vs AZN Comparison
SKHY vs AZN Comparison
Compare SKHY & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKHY | AZN |
|---|---|---|
| Founded | N/A | 1992 |
| Country | South Korea | United Kingdom |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 979.0B | 316.4B |
| IPO Year | 2026 | 1995 |
Fundamental Metrics
Financial Performance| Metric | SKHY | AZN |
|---|---|---|
| Price | $163.29 | $165.98 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 27.2M | 4.0M |
| Earning Date | N/A | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.34 |
| Revenue Next Year | N/A | $6.43 |
| P/E Ratio | ★ N/A | $31.91 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $124.80 | $72.90 |
| 52 Week High | $178.43 | $212.71 |
Technical Indicators
Market Signals| Indicator | SKHY | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 54.80 | 51.30 |
| Support Level | $154.53 | $164.06 |
| Resistance Level | $178.18 | $175.04 |
| Average True Range (ATR) | 8.00 | 2.73 |
| MACD | 1.81 | 1.24 |
| Stochastic Oscillator | 66.66 | 90.40 |
Price Performance
Historical ComparisonAbout SKHY SK hynix Inc. American Depositary Shares
SK Hynix is a semiconductor memory manufacturer with around 60%-70% of its revenue from DRAM and 30%-35% of its revenue from NAND. The company is both the second-largest DRAM and NAND supplier globally, with a 33% and 21% market share, respectively, as of 2024. SK Hynix increased its market position in NAND from fourth to second, after acquiring Intel's NAND business in 2021. SK Square, an investment management company spun off from SK Telecom, is SK Hynix's largest shareholder and currently holds 20% of the company's shares.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.